AstraZeneca Pharma India Limited (IN:ASTRAZEN)
:ASTRAZEN
ASTRAZEN Stock Chart & Stats
₹8431.70
₹585.60(8.51%)
At close: 4:00 PM EST
₹8431.70
₹585.60(8.51%)
Day’s Range― - ―
52-Week Range₹6,501.60 - ₹10,653.05
Previous CloseN/A
Volume65.42K
Average Volume (3M)602.00
Market Cap
₹198.65B
Enterprise Value₹194.63B
Total Cash (Recent Filing)₹4.10B
Total Debt (Recent Filing)₹347.90M
Price to Earnings (P/E)173.1
Beta0.77
Next Earnings
May 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.35%
Share Statistics
EPS (TTM)13.04
Shares Outstanding25,000,000
10 Day Avg. Volume682
30 Day Avg. Volume602
Financial Highlights & Ratios
PEG Ratio-6.48
Price to Book (P/B)27.56
Price to Sales (P/S)12.37
P/FCF Ratio333.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthConsistent multi-year revenue growth more than doubled reported sales from 2022–2025, indicating durable demand across therapy areas. This supports scalable commercial investment, improves bargaining with channels, and underpins longer-term product launch economics in India.
Strong Cash GenerationImproved conversion of earnings into cash reduces funding risk and funds working capital, launches, and marketing without heavy external financing. Reliable cash generation enhances operational resilience and allows steady reinvestment into key specialty and chronic therapy franchises.
Conservative Capital StructureVery low leverage and a stronger equity base provide financial flexibility to invest in commercial expansion or absorb shocks. A healthier equity ratio reduces refinancing risk and supports sustained R&D/marketing spend for long-cycle pharmaceutical product commercialization.
Bears Say
Profitability CompressionA sharp decline in net margins halves bottom-line profitability despite revenue growth, signaling rising cost pressure or pricing limitations. If persistent, margin erosion will reduce free cash flow per rupee revenue and constrain long-term reinvestment and shareholder returns.
Rising Total LiabilitiesAn increasing liability base raises contingent funding needs even with low reported leverage. If liabilities grow faster than cash generation, liquidity could tighten under stress, limiting flexibility to fund launches or absorb pricing/regulatory headwinds over the medium term.
Dependence On Parent's PortfolioBusiness model relies on parent-supplied brands and portfolio decisions, restricting control over pipeline, pricing and supply. Strategic changes at the parent or shifts in global allocation could materially affect local product mix and long-term growth autonomy.
AstraZeneca Pharma India Limited News
ASTRAZEN FAQ
What was AstraZeneca Pharma India Limited’s price range in the past 12 months?
AstraZeneca Pharma India Limited lowest stock price was ₹6501.60 and its highest was ₹10653.05 in the past 12 months.
What is AstraZeneca Pharma India Limited’s market cap?
AstraZeneca Pharma India Limited’s market cap is ₹198.65B.
When is AstraZeneca Pharma India Limited’s upcoming earnings report date?
AstraZeneca Pharma India Limited’s upcoming earnings report date is May 27, 2026 which is in 59 days.
How were AstraZeneca Pharma India Limited’s earnings last quarter?
AstraZeneca Pharma India Limited released its earnings results on Feb 11, 2026. The company reported ₹13.036 earnings per share for the quarter, beating the consensus estimate of N/A by ₹13.036.
Is AstraZeneca Pharma India Limited overvalued?
According to Wall Street analysts AstraZeneca Pharma India Limited’s price is currently Overvalued.
Does AstraZeneca Pharma India Limited pay dividends?
AstraZeneca Pharma India Limited pays a Annually dividend of ₹32 which represents an annual dividend yield of 0.35%. See more information on AstraZeneca Pharma India Limited dividends here
What is AstraZeneca Pharma India Limited’s EPS estimate?
AstraZeneca Pharma India Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AstraZeneca Pharma India Limited have?
AstraZeneca Pharma India Limited has 25,000,000 shares outstanding.
What happened to AstraZeneca Pharma India Limited’s price movement after its last earnings report?
AstraZeneca Pharma India Limited reported an EPS of ₹13.036 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.299%.
Which hedge fund is a major shareholder of AstraZeneca Pharma India Limited?
Currently, no hedge funds are holding shares in IN:ASTRAZEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, distributes, and markets pharmaceutical products in India and internationally. It manufactures and sells cardiovascular disease and diabetes medicines under the Brilinta, Betaloc, Crestor, Forxiga, Imdur, Kombiglyze XR, Onglyza, Seloken XL, Xigduo XR, and QTERN brands; Respiratory medicines under the Symbicort and FASENRA brand names; and oncology medicines under the LYNPARZA, Tagrisso, Iressa, Calquence, Casodex, Faslodex, Zoladex, and Arimidex brands. The company also offers products in the areas of renal, metabolic, and immunology diseases. It also provides clinical trial services. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.
Technical Analysis
Alkem Laboratories Ltd.
―
GlaxoSmithKline Pharmaceuticals Limited
―
Glenmark Pharmaceuticals Limited
―